Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for Closed-Loop Blood Glucose Control Devices, effective May 15, 2026. Here's what billing teams need to do.
CMS closed-loop blood glucose control device coverage policy updates don't come often, but when they do, they carry real reimbursement exposure. This modification affects durable medical equipment suppliers, endocrinology practices, and any billing team submitting claims for automated insulin delivery systems under Medicare. The policy document does not list specific CPT or HCPCS codes — we'll cover what that means for your billing team below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Closed-Loop Blood Glucose Control Device (CBGCD) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Endocrinology, DME suppliers, internal medicine, primary care, diabetes management programs |
| Key Action | Audit your closed-loop system claims and prior authorization workflows before May 15, 2026 |
CMS Closed-Loop Blood Glucose Control Device Coverage Criteria and Medical Necessity Requirements 2026
Closed-loop blood glucose control devices — also called automated insulin delivery (AID) systems or artificial pancreas devices — combine a continuous glucose monitor (CGM), an insulin pump, and a control algorithm that adjusts insulin delivery automatically. That integration is exactly what makes the billing complex. You're often coding across multiple HCPCS categories for a single device system.
CMS medical necessity criteria for these devices have historically required a confirmed diagnosis of diabetes mellitus, documented failure or inadequacy of conventional insulin therapy, and physician oversight with documented treatment planning. Medical necessity documentation needs to show the clinical rationale for why a closed-loop system is appropriate over standard pump therapy or multiple daily injections.
The modified coverage policy signals CMS is refining how it evaluates these criteria. Given the pace at which new closed-loop systems have entered the market — Abbott, Medtronic, Insulet, and Tandem all have cleared systems — a policy modification this year is consistent with CMS catching its coverage framework up to the current device landscape.
If you're billing for closed-loop systems under Medicare, prior authorization requirements are the first thing to check. CMS has been expanding prior auth programs for DME categories, and closed-loop systems — given their cost — are a natural target. Confirm with your Medicare Administrative Contractor whether prior authorization applies in your region before May 15, 2026.
CMS Closed-Loop Blood Glucose Control Device Exclusions and Non-Covered Indications
The policy document provided does not include explicit exclusion language. That said, based on how CMS has historically structured coverage for these devices, several non-covered scenarios consistently appear across MAC-level local coverage determinations.
Closed-loop systems used without an active treating physician relationship are typically denied. Claims without supporting documentation of diagnosis, inadequate response to simpler therapy, or device-specific training completion will trigger claim denial. If the device is prescribed for type 2 diabetes without insulin dependence, expect scrutiny — most MAC policies limit coverage to insulin-dependent patients.
Devices used purely for glucose monitoring without the insulin delivery component don't qualify under CBGCD coverage. Those claims fall under CGM-specific HCPCS codes, not closed-loop device codes. Mixing these up in charge capture is a common and costly error.
Coverage Indications at a Glance
The source policy document does not provide specific indication-level coverage criteria. The table below reflects CMS's general coverage framework for closed-loop blood glucose control devices based on established Medicare coverage principles. Verify against your MAC's current local coverage determination before billing.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Insulin-dependent diabetes mellitus with documented inadequate control | Covered (when criteria met) | Not specified in this policy | Medical necessity documentation required |
| Type 1 diabetes with physician-supervised management plan | Covered (when criteria met) | Not specified in this policy | Prior authorization may apply — confirm with your MAC |
| Type 2 diabetes, insulin-dependent, with documented clinical need | Coverage varies by MAC | Not specified in this policy | Check your local coverage determination |
| Non-insulin-dependent type 2 diabetes | Not Covered | N/A | CGM-only coverage may apply under separate policy |
| Closed-loop device use without active prescribing physician | Not Covered | N/A | Physician oversight is a coverage requirement |
| Device components billed separately without integrated system documentation | Claim Denial Risk | N/A | Bundle coding accuracy is critical |
CMS Closed-Loop Blood Glucose Control Device Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull your MAC's current LCD before May 15, 2026. The Centers for Medicare & Medicaid Services sets national coverage direction, but your Medicare Administrative Contractor sets the local coverage determination that actually governs claim adjudication in your region. Closed-loop billing guidelines vary by MAC — what's covered in one jurisdiction may require additional documentation in another. |
| 2 | Audit your prior authorization workflow now. CMS has expanded prior auth requirements across DME categories. Closed-loop blood glucose control device billing carries high per-claim value, which means claim denial without prior auth is an expensive miss. Confirm your PA process reflects current requirements before the effective date. |
| 3 | Review your charge capture for the full device system. Closed-loop systems involve at least three components: the CGM sensor and transmitter, the insulin pump, and the algorithm controller. Each may have separate HCPCS codes. Confirm your charge capture maps the full system correctly — not just the pump or just the sensor. |
| 4 | Update your medical necessity documentation templates. Your physician documentation needs to support the specific criteria CMS requires: confirmed diagnosis, insulin dependence, inadequate response to prior therapy, and a documented management plan. If your intake templates don't prompt for all of these, fix them before May 15, 2026. |
| 5 | Check for bundling conflicts. If your patients are also billing for standalone CGM supplies, confirm your coding doesn't create a bundling conflict with the closed-loop system claims. CMS edits for duplicate billing across CGM and closed-loop HCPCS codes are a consistent source of denials in this category. |
| 6 | Talk to your compliance officer about the policy modification scope. CMS hasn't published specific code-level changes in the available policy data, which makes the exact scope of this modification ambiguous. That ambiguity is a compliance risk. If you're billing significant volume in this category, loop in your compliance officer before May 15, 2026 to assess exposure. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Closed-Loop Blood Glucose Control Devices Under CMS Policy
No Specific Codes Listed in This Policy
The CMS Closed-Loop Blood Glucose Control Device policy document does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for a CMS national policy modification at this level — code-specific guidance typically lives at the MAC LCD level or in separate HCPCS code descriptor updates.
Do not use this policy document alone to determine code selection. Code-level coverage decisions for closed-loop devices depend on your MAC's local coverage determination, the specific device cleared by the FDA, and HCPCS code descriptors that CMS updates separately through its annual HCPCS process.
Where to Find the Applicable Codes
Cross-reference these sources to build your complete code set:
| Source | What It Covers |
|---|---|
| Your MAC's LCD for closed-loop/automated insulin delivery | Code-specific coverage criteria and ICD-10 diagnosis code lists |
| CMS HCPCS Annual Update | New or revised HCPCS Level II codes for DME device categories |
| DMEPOS fee schedule | Reimbursement rates by HCPCS code and region |
| CMS Coding Contractor (PDAC) | Correct HCPCS code assignment for specific device models |
The real issue here is that CMS policy modifications often precede the code-level updates that follow in LCD revisions or fee schedule changes. Watch for MAC-level LCD updates tied to this CMS policy change through the rest of 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.